These opposing results extend to other cancer types and in vivo studies (259, 260), which suggest that loss of IFN signaling sensitizes tumor cells to lymphocyte-mediated cell killing and, more broadly, to immunotherapy. The gene discussed is IFNA1; the disease is neoplasm.